Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FRTX-02
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FRTX-02 is a highly selective, and orally bioavailable potential first-in-class dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor that is currently being evaluated in Phase 1 clinical trial for atopic dermatitis and rheumatoid arthr...
Product Name : FRTX-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : FRTX-02
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Botanix Pharma
Deal Size : $8.2 million
Deal Type : Agreement
Details : Under the agreement, Fresh Tracks provided consulting services as an independent contractor to Botanix in support of and through filing and approval of the U.S. new drug application for BBI-4000 (sofpironium bromide gel).
Product Name : BBI-4000
Product Type : Other Small Molecule
Upfront Cash : $8.2 million
July 21, 2023
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Botanix Pharma
Deal Size : $8.2 million
Deal Type : Agreement
Lead Product(s) : FRTX-02
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FRTX-02 is a potential dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor that aims to restore immune balance by modulating both adaptive and innate immune responses in patients with autoimmune and inflammatory diseases.
Product Name : FRTX-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : FRTX-02
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FRTX-02
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FRTX-02 is potent, highly selective, and orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance by modulating both adaptive and innate immune responses in patients with autoimmune and inflammatory diseases.
Product Name : FRTX-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : FRTX-02
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBI-02
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
Details : BBI-02 is a highly selective and orally bioavailable DYRK1A (dual specificity tyrosine-phosphorylation-regulated kinase 1A) inhibitor that has demonstrated promising results in various preclinical models, including atopic dermatitis and rheumatoid arthri...
Product Name : BBI-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : BBI-02
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $8.0 million
Deal Type : Public Offering
Brickell Biotech Closing of $8.05 Million Bought Deal Offering , Including Full Exercise
Details : Sofpironium bromide is Brickell’s lead investigational product candidate and is a new chemical entity that belongs to a class of medications called anticholinergics.
Product Name : BBI-4000
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 22, 2021
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $8.0 million
Deal Type : Public Offering
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from the Cardigan I and Cardigan II studies, along with all previously completed clinical studies, will form the basis for a U.S. NDA for sofpironium bromide gel, 15%, which is expected to submit to the FDA in mid-2022.
Product Name : BBI-4000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brickell Biotech completed patient enrollment in the Phase 3 pivotal Cardigan I study and that the Cardigan II study has surpassed 50% enrollment. Both studies are evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyper...
Product Name : BBI-4000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2021
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ARGYLE study assessed the long-term safety and efficacy of topical, once-daily treatment with sofpironium bromide gel, 5% and 15% for 48 weeks in patients nine years and older with primary axillary hyperhidrosis/excessive underarm sweating.
Product Name : BBI-4000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The application for sofpironium bromide in Japan involves data from the Phase 3 study in Japan, targeting patients with primary axillary hyperhidrosis, in which positive results were obtained.
Product Name : BBI-4000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2020
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable